兔抗erbb2多---抗体

backg

round:

the erbb2 (her2) proto-oncogene encodes a 185 kda transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity. while erbb2 lacks an identified ligand, erbb2 kinase activity can be activated in the absence of a ligand when overexpressed&through heteromeric asso---tions with other erbb family members. amplification of the erbb2 gene&overexpression of its product are detected in almost 40% of human breast cancers. binding of the c-cbl ubiquitin ligase to erbb2 at tyr1112 leads to erbb2 poly-ubiquitination&enhances degradation of this kinase. erbb2 is a key therapeutic target in the treatment of breast cancer&other carcinomas&targeting the regulation of erbb2 degradation by the c-cbl-regulated proteolytic pathway is one potential therapeutic strategy. phosphorylation of the kinase domain residue tyr877 of erbb2 (homologous to tyr416 of pp60c-src) may be involved in regulating erbb2 biological activity. the major autophosphorylation sites in erbb2 are tyr1248&tyr1221/1222; phosphorylation of these sites couples erbb2 to the ras-raf-map kinase signal transduction pathway.

applica

tions:

elisa, wb, ihc

name of antibody:

erbb2

immunogen:

synthetic peptide of human erbb2

full name:

erb-b2 receptor tyrosine kinase 2

synonyms:

neu; ngl; her2; tkr1; cd340; her-2; mln 19; her-2/neu

swissprot:

p04626

elisa recomme

nded dilution:

5000-10000

ihc positive control:

human brain&human ovarian cancer

ihc recom

mend dilution:

20-100

wb predicted band size:

138 kda

wb positive control:

231&hela cell lysates

wb recomme

nded dilution:

200-1000